Key Takeaways Adjusted earnings per share of $2.91 surpassed analyst expectations of $2.42 Company projects full-year adjusted EPS between $12.40 and $12.60, above the $12.08 consensus Total
Cardinal Health delivered a contrasting fiscal fourth-quarter report Tuesday, combining disappointing revenue figures with an optimistic annual earnings projection that caught investor attention.
CARDINAL HEALTH $CAH Q4’26 EARNINGS HIGHLIGHTS
Revenue: $63.7B (Est. $65B)
; +6% YoY
; +40% YoY
IEEPA Tariff Refund: $100M operating profit impact; $0.31 EPS impact
FY27 Guide:… pic.twitter.com/HbBlV1UQfE
— Wall St Engine (@wallstengine) August 11, 2026
The company’s adjusted earnings per share reached $2.91 for the period, surpassing Wall Street’s $2.42 projection. Within that total was a 31-cent contribution from tariff-related refunds, bringing the core figure to $2.60.
Total revenue advanced 6% from the prior-year quarter to $63.67 billion. The figure fell below analysts’ expectations of $65.15 billion.
CAH shares slipped 0.8% during Tuesday’s premarket hours.
Under generally accepted accounting principles, net earnings totaled $398 million, translating to $1.70 per share. The prior-year quarter recorded $239 million in net income, equivalent to $1.00 per share.
The pharmaceutical division delivered 6% revenue expansion, propelled by increased order volumes from current clients and strong generic medication sales.
The global medical products and distribution unit represented the underperformer. Sales in this division dropped 2%, pressured by reduced distribution activity and the accounting impact of anticipated tariff refund reimbursements to clients.
This divergent performance warrants attention as Cardinal pushes into emerging growth markets.
Looking to the upcoming fiscal year, Cardinal Health forecasted adjusted earnings per share ranging from $12.40 to $12.60. This projection signals 13% to 15% expansion and substantially exceeds the FactSet consensus estimate of $12.08.
Management anticipates pharmaceutical revenue will rise 3% to 5%, while medical products and distribution should grow 2% to 4%.
This outlook incorporates recent strategic expansions into home healthcare services, such as the Strive Medical purchase and the planned acquisition of AdaptHealth’s diabetes operations.
The company additionally unveiled a fresh $4 billion revolving credit facility extending through 2031. This arrangement consolidates three previous credit lines.
The post Cardinal Health (CAH) Stock: Robust FY Forecast Overshadows Q4 Revenue Shortfall appeared first on Blockonomi.
